Catalyst Event

Pfizer Inc (PFE) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

5/13/2026, 12:00:00 AM

OtherSentiment: Positive

The European Commission granted marketing authorization for HYMPAVZI (marstacimab) on 2026-05-13 for the treatment of adults and adolescents with hemophilia A or B with inhibitors (Low importance as a standard regulatory approval).

Korean Translation

2026년 5월 13일, 유럽연합 집행위원회는 억제인자를 보유한 혈우병 A 또는 B 성인 및 청소년 환자 치료를 위한 힘파브지(HYMPAVZI, marstacimab)의 판매를 승인함(통상적인 규제 승인에 따른 낮은 영향 예상).

Related Recent Events

View Full Timeline